WebMay 3, 2024 · Alternatively, given the 100% recurrence risk in patients where ctDNA is persistently detectable after adjuvant chemotherapy, this is a patient group where the value of further therapy with novel systemic strategies or more intensive surveillance should be explored in clinical trials. ctDNA clearance rate could also be used as a “go/no-go ... WebJun 8, 2024 · LBA100 Background: The role of adjuvant chemotherapy (CT) in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival (RFS), while its absence predicts a low recurrence risk. For ctDNA-positive cases the benefit of adjuvant CT is unknown. …
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal ...
WebOct 13, 2024 · Post-surgical, or adjuvant, treatment with pembrolizumab also lowered the risk of the melanoma recurring in other parts of the body, a significant concern with this form of skin cancer. The nearly 1,000 patients in the trial, called KEYNOTE-716 , had melanoma that had been classified as either stage IIB or stage IIC. WebDec 1, 2024 · During this period, 24 patients (25%) experienced a recurrence, including 18 of 85 patients (21%) treated with at least 12 weeks of adjuvant chemotherapy, 15 of 72 (21%) who completed 24 weeks of adjuvant chemotherapy, and 1 of 1 (100%) who did not receive chemotherapy. Postsurgical ctDNA was detectable in 10 of 24 patients (42%) … city jobs sioux city
[PDF] Dynamic recurrence risk and adjuvant chemotherapy …
WebJan 16, 2024 · ctDNA is a minimally invasive biomarker that can aid in the measurement of disease status across several settings, including postcurative surgery or treatment for … WebApr 11, 2024 · CA19-9 dynamic after adjuvant GEM × 3, no. (%) ... Consolidation CRT after completion of standard adjuvant chemotherapy in patients at a high risk of locoregional recurrence and low risk of distant metastasis, selected by novel molecular biomarkers, is a reasonable design for future adjuvant CRT trials in resected PDAC. ... WebNov 18, 2024 · Positive postoperative ctDNA results had poor outcomes despite adjuvant treatment, with a three-year recurrence-free interval of 47% vs. 76% in patients with negative postoperative ctDNA, indicating that ctDNA analysis might serve as a prognostic biomarker for recurrence risk and adjuvant therapy benefit in stage III colon cancer . city jobs kansas city mo